BEAM THERAPEUTICS INC (BEAM:NASDAQ)
$25.75 0.68 (2.7124%)
Analysed BEAM THERAPEUTICS INC (BEAM:NASDAQ) News Sources
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
08-07-2026
stocktwits.com
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
08-07-2026
yahoo.com
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
09-07-2026
yahoo.com
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?
09-07-2026
yahoo.com
Kyverna Therapeutics Sinks 13%: Here’s Why
10-07-2026
247wallst.com
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
15-07-2026
yahoo.com
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
15-07-2026
yahoo.com
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
20-07-2026
fool.com
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
23-07-2026
yahoo.com
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
27-07-2026
yahoo.com
What is the current price of BEAM THERAPEUTICS INC (BEAM:NASDAQ)?
The current price of BEAM THERAPEUTICS INC (BEAM:NASDAQ) is $25.75.
BEAM THERAPEUTICS INC (BEAM:NASDAQ) absolute price change since previous trading day?
The absolute price change of BEAM THERAPEUTICS INC (BEAM:NASDAQ) since the previous trading day is $0.68.
BEAM THERAPEUTICS INC (BEAM:NASDAQ) percentage price change since previous trading day?
The percentage price change of BEAM THERAPEUTICS INC (BEAM:NASDAQ) since the previous trading day is 2.7124%.
What is the most recent average sentiment score for BEAM THERAPEUTICS INC (BEAM:NASDAQ)?
The most recent average sentiment score for BEAM THERAPEUTICS INC (BEAM:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for BEAM THERAPEUTICS INC (BEAM:NASDAQ)?
The most recent sentiment for BEAM THERAPEUTICS INC (BEAM:NASDAQ) is .
SEC-8K** Filing Available For BEAM THERAPEUTICS INC (BEAM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.